Edition:
United Kingdom

Landec Corp (LNDC.OQ)

LNDC.OQ on NASDAQ Stock Exchange Global Select Market

13.49USD
17 Oct 2018
Change (% chg)

$0.06 (+0.45%)
Prev Close
$13.43
Open
$13.38
Day's High
$13.52
Day's Low
$13.34
Volume
8,947
Avg. Vol
16,051
52-wk High
$15.60
52-wk Low
$11.60

Summary

Name Age Since Current Position

Steven Goldby

78 2015 Independent Chairman of the Board

Molly Hemmeter

51 2015 President, Chief Executive Officer

Gregory Skinner

57 2000 Chief Financial Officer, Vice President - Finance and Administration

James Hall

55 2017 President of Lifecore

Steven Bitler

60 2002 Vice President - Corporate Technology

Albert Bolles

61 2014 Independent Director

Deborah Carosella

61 2017 Independent Director

Frederick Frank

86 1999 Independent Director

Nelson Obus

71 Independent Director

Tonia Pankopf

50 2012 Independent Director

Andrew Powell

60 Independent Director

Catherine Sohn

65 2012 Independent Director

Robert Tobin

80 2004 Independent Director

Matt Glover

IR Contact Officer

Biographies

Name Description

Steven Goldby

Mr. Steven D. Goldby is Independent Chairman of the Board of the Company. Mr. Goldby has served as a director since December 2008 and is currently the Board’s Outside Lead Independent Director and a sitting member of the Audit Committee. Mr. Goldby has been a Partner at Venrock, a venture capital firm, since 2007. Mr. Goldby was Chairman and Chief Executive Officer of Symyx Technologies, Inc. (“Symyx”) from 1998 to 2007; he became the Executive Chairman in 2008, and Chairman in 2009. Before joining Symyx, Mr. Goldby served as Chief Executive Officer for more than ten years at MDL Information Systems, Inc., the enterprise software company that pioneered scientific information management. Earlier, Mr. Goldby held various management positions at ALZA Corporation, including President of Alza Pharmaceuticals. Mr. Goldby received a B.S. degree in chemistry from the University of North Carolina and a law degree from Georgetown University Law Center.

Molly Hemmeter

Ms. Molly A. Hemmeter serves as President, Chief Executive Officer of the Company. Prior to which she served as Chief Commercial Officer of the Company from December 2010 to January 2014 and Vice President, Business Development and Global Marketing of the Company from June 2009 to December 2010. From July 2006 until joining the Company in June 2009, Ms. Hemmeter was Vice President of Global Marketing and New Business Development for the Performance Materials division of Ashland, Inc., a global specialty chemicals company. Prior to joining Ashland, Inc., Ms. Hemmeter was Vice President of Strategy and Marketing for Siterra Corporation and Chief Marketing Officer for CriticalArc Technologies in the San Francisco Bay Area, both of which were privately held software startup companies that were eventually acquired by larger entities, and she previously held various positions at Bausch & Lomb and Eli Lilly and Company.

Gregory Skinner

Mr. Gregory S. Skinner is Chief Financial Officer, Vice President - Finance and Administration of the Company. From May 1996 to October 1999, Mr. Skinner served as Controller of the Company. From 1994 to 1996, Mr. Skinner was Controller of DNA Plant Technology and from 1988 to 1994 he was with Litton Electron Devices. Prior to joining Litton Electron Devices, Mr. Skinner was with Litton Industries, Inc. and Arthur Anderson & Company.

James Hall

Mr. James G. Hall is appointed as President of Lifecore of the subsidiary of the company effective on June 1, 2017. At Lifecore, Mr. Hall served as Vice President and General Manager from July 2013 to June 2017, Vice President of Operations from 2006 to 2013; Director of Manufacturing Operations and Engineering from 2001 to 2006; and the Manager of Engineering and Operations from 1999 to 2001. From 1995 until joining Lifecore in 1999, Mr. Hall was Manager of Pre-Clinical and Clinical supply for Protein Design Labs, a biotechnology company focusing on humanizing monoclonal antibodies. Prior to joining Protein Design Labs in 1995, Mr. Hall held various engineering positions within Lifecore beginning in 1989. Mr. Hall has over 29 years of pharmaceutical and combination product manufacturing and development experience.

Steven Bitler

Dr. Steven P. Bitler, Ph.D., serves as Vice President - Corporate Technology of the Company. From 1988 until March 2002, Dr. Bitler held various positions with the Company related to the Company’s polymer product development and thermal switch products. Prior to joining the Company, Dr. Bitler developed new high strength polymeric materials at SRI International.

Albert Bolles

Dr. Albert D. Bolles, Ph.D. is Independent Director of the company. He also served as Retired Executive Vice President and Chief Technical and Operations Officer, ConAgra Foods, Inc., until his retirement in August 2015. Dr. Bolles leads the Research, Quality & Innovation and Supply Chain organizations for ConAgra Foods, which is one of North America's largest packaged food companies. The company's portfolio includes iconic consumer brands such as Hunt's, Chef Boyardee and Reddi-wip, plus the largest private brand package food business in North America, and a strong commercial and foodservice business. Dr. Bolles has been with ConAgra, an $18 billion food company, since 2006 and reports directly to the CEO. Dr. Bolles has led innovation programs for multiple new products, generating incremental sales and a multi-year pipeline to sustain and advance future growth. In advancing innovation at ConAgra, Dr. Bolles developed two external scientific advisory boards comprised of nationally recognized leaders to shape strategy and create industry leadership for ConAgra in Health & Wellness and Food Safety. As an industry partner with the FDA and USDA on influencing and crafting public policy that benefits consumers, Dr. Bolles was instrumental in the passage of the Food Safety Modernization Act in 2010. Dr. Bolles holds six patents. He is a graduate of Michigan State University with a B.S. in Microbiology plus an M.S. and Ph.D. in Food Science.

Deborah Carosella

Ms. Deborah B. Carosella serves as Independent Director of the Company. She is a member of the Company's Food Innovation Committee. Ms. Carosella was most recently the CEO of Madhava Natural Sweeteners, focused on innovating honey and agave-based products that provide an alternative to highly processed refined sugars and artificial sweeteners. Ms. Carosella led the transformation of Madhava, meaning "born of honey", from a base of commodity products to a broad line of value-added branded products, doubling sales and margins over the four years of her leadership. Previously, Ms. Carosella was the Senior Vice President of Innovation and a meber of the Executive Operating Team at Whitewave Foods, currently in the process of being acquired by European food giant, Danone SA. Previous to Whitewave, she led the innovation efforts at Dean Foods, where she built the innovation function, capabilities and processes used at both Whitewave and Dean Foods. Prior to Dean Foods, Ms. Carosella was Vice President and General Manager as well as Vice President of Strategic Marketing and Innovation at ConAgra Foods. Accomplishments at ConAgra included driving double-digit revenue and profit growth and creating, developing and commercializing one of the company's most successful product launches in its history, which delivered over $100 million in sales in its first year. Before ConAgra, Ms. Carosella was Vice President Consumer Nutrition Brand Strategy at Monsanto Company. Ms. Carosella is a graduate of the University of Missouri.

Frederick Frank

Mr. Frederick Frank is Independent Director of the Company. Mr. Frank is Chairman of the Board of Evolution Life Sciences Partners. Prior to joining Evolution Partners, Mr. Frank was Chairman of the Board of Burrill Securities. Prior to joining Burrill Securities, Mr. Frank was Vice Chairman of Peter J. Solomon Company (“Solomon”). Before joining Solomon, Mr. Frank was Vice Chairman of Lehman Brothers, Inc. (“Lehman”) and Barclays Capital. Before joining Lehman as a Partner in October 1969, Mr. Frank was co-director of research, as well as Vice President and Director of Smith Barney & Co. Incorporated. During his over 50 years on Wall Street, Mr. Frank has been involved in numerous financings and merger and acquisition transactions. He serves as an advisor to the board of directors of PDL BioPharma, and was a director for the Institute for Systems Biology and Pharmaceutical Product Development, Inc. Mr. Frank is Chairman of the National Genetics Foundation and he serves on the Advisory Boards for Yale School of Organization and Management, the Massachusetts Institute of Technology Center of Biomedical Innovation and was formerly an Advisory Member of the Johns Hopkins Bloomberg School of Public Health, and the Harvard School of Public Health. He is a graduate of Yale University, received an M.B.A. from Stanford University and is a Chartered Financial Analyst.

Nelson Obus

Mr. Nelson Obus serves as Independent Director of the company. Mr. Obus is Managing Member of Wynnefield Capital Management, LLC and a General Partner at Wynnefield Capital, Inc. and his prior associations include positions with Schaffer Capital Management and Lazard Freres. Mr. Obus presently serves on the Board of Directors of Global Power Equipment Group Inc. and MK Acquisition LLC and previously served on the Boards of Layne Christensen Company, Breeze-Eastern Corporation and Underground Solutions Inc. Mr. Obus holds a bachelor of the arts degree from New York University and a master of arts in political science from Brandeis University.

Tonia Pankopf

Ms. Tonia Pankopf is Independent Director of the Company. Ms. Pankopf has been managing partner of Pareto Advisors, LLC since 2005. Previously, she was a senior analyst and managing director at Palladio Capital Management from January 2004 through April 2005. From 2001 to 2003, Ms. Pankopf served as an analyst and portfolio manager with P.A.W. Capital Partners, LP. Ms. Pankopf was a senior analyst and vice president at Goldman, Sachs & Co. from 1999 to 2001 and at Merrill Lynch & Co. from 1998 to 1999. Ms. Pankopf serves on the Board of Directors of TICC Capital Corp. and served on the Board of the University System of Maryland Foundation from 2006 to 2012. Ms. Pankopf is a member of the National Association of Corporate Directors and has been designated an NACD Governance Fellow in recognition of her ongoing involvement in director professionalism and engagement with the director community. Ms. Pankopf received a Bachelor of Arts degree summa cum laude from the University of Maryland and an M.S. degree from the London School of Economics.

Andrew Powell

Mr. Andrew Kenneth William Powell serves as Independent Director of the company. Mr. Powell is currently serving as an independent advisor to small and mid-size companies and research institutions in the life sciences sector. He has served on the Board of Directors of Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, since 2017. He served as Senior Vice President, General Counsel and Corporate Secretary of Medivation, Inc. from May 2015 until November 2016, when the company was acquired by Pfizer, Inc. Mr. Powell served as Executive Vice President, General Counsel and Corporate Secretary of InterMune, Inc. from September 2013 to March 2015. From 2009 to 2013, he served as Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics, Inc. From 2008 to 2009, Mr. Powell served as Senior Vice President and General Counsel at ImClone Systems, Inc. From 2004 to 2008, he was General Counsel at Collagenex Pharmaceuticals, Inc. Earlier in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multi-national healthcare company Baxter International, Inc., where he was instrumental in a series of transactions that established Baxter throughout Asia. Mr. Powell holds a Bachelor of Arts degree from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School.

Catherine Sohn

Dr. Catherine A. Sohn is Independent Director of the Company. Dr. Sohn brings significant industry experience in pharmaceutical and health-related sectors based on her leadership and achievements in business development and new product development for 28 years at Glaxo Smith Kline (“GSK”). Most recently, Dr. Sohn was Senior Vice President of Worldwide Business Development and Strategic Alliance for GSK’s $8 billion consumer healthcare division. Early in her career, Dr. Sohn established the U.S. vaccine business unit for SmithKline Beecham Pharmaceuticals and she subsequently led the commercialization of Paxil, which became one of GSK’s top five pharmaceutical products. Currently Dr. Sohn serves as president of Sohn Health Strategies, LLC, providing business development and new product marketing consultation to biotechnology, specialty pharmaceutical and healthcare companies. Dr. Sohn is a National Association of Corporate Directors (NACD) Governance Fellow. She has demonstrated her commitment to boardroom excellence by completing NACD’s comprehensive program of study for corporate directors. She supplements her skill sets through ongoing engagement with the director community and access to leading practices. Dr. Sohn received her Doctor of Pharmacy degree from University of California in San Francisco.

Robert Tobin

Mr. Robert G. Tobin is Independent Director of the Company. Mr. Tobin retired from his position as Chief Executive Officer of Ahold USA in 2001. Mr. Tobin has over 40 years of industry experience in the food retail and food service sectors, having served as Chairman and CEO of Stop and Shop Supermarkets. An industry leader, Mr. Tobin serves on the advisory boards of the College of Agriculture and Life Sciences and the Undergraduate Business Program at Cornell University where he received his B.S. in Agricultural Economics.

Matt Glover

Basic Compensation

Name Fiscal Year Total

Steven Goldby

150,000

Molly Hemmeter

1,292,700

Gregory Skinner

728,934

James Hall

1,028,410

Steven Bitler

372,309

Albert Bolles

137,500

Deborah Carosella

119,688

Frederick Frank

122,500

Nelson Obus

--

Tonia Pankopf

130,000

Andrew Powell

--

Catherine Sohn

123,478

Robert Tobin

120,000

Matt Glover

--
As Of  29 May 2018